What is the evidence‑based first‑line vasopressor for septic shock, including recommended dosing and subsequent vasopressor options if the target blood pressure is not achieved?

Vasopressor Management in Septic Shock

Norepinephrine is the first-line vasopressor for septic shock, targeting an initial mean arterial pressure (MAP) of 65 mmHg. 1, 2

First-Line Vasopressor: Norepinephrine

The Surviving Sepsis Campaign guidelines provide a strong recommendation (Grade 1B) for norepinephrine as the first-choice vasopressor, supported by moderate quality evidence 1. This recommendation is reinforced by meta-analysis data demonstrating that norepinephrine reduces all-cause mortality compared to dopamine (RR 0.89,95% CI 0.81-0.98), translating to an absolute risk reduction of 11% and a number needed to treat of 9 3. Norepinephrine also carries a lower risk of cardiac arrhythmias and major adverse events compared to dopamine 3.

Initial MAP target: 65 mmHg (Grade 1C) 1, 2. While this is the standard initial target, patients with chronic hypertension may require higher targets based on individualized assessment.

Second-Line Vasopressor Options When Target BP Not Achieved

When norepinephrine alone fails to achieve target MAP, the guidelines recommend adding a second vasopressor rather than escalating norepinephrine to very high doses:

Option 1: Add Vasopressin (Preferred Second-Line)

• Dose: 0.03 units/minute (fixed dose) 1, 2
• Grade 2B recommendation (weak recommendation, moderate quality evidence) 1
• Add vasopressin when norepinephrine requirements exceed 0.25-0.50 µg/kg/min 4
• Benefits: Norepinephrine-sparing effect, reduced risk of atrial fibrillation 4, 5
• Caution: Increased risk of digital ischemia 5
• Critical limitation: Do NOT use vasopressin as a single initial vasopressor; doses higher than 0.03-0.04 units/minute should be reserved for salvage therapy only 1, 2

Option 2: Add Epinephrine

• Grade 2B recommendation (weak recommendation, low quality evidence) 1
• Can be added to norepinephrine or potentially substituted for it when an additional agent is needed 1, 2
• Particularly useful when cardiac dysfunction coexists with vasodilatory shock

Alternative and Salvage Vasopressors

Dopamine (Limited Role)

• Only for highly selected patients with low risk of tachyarrhythmias AND absolute or relative bradycardia (Grade 2C) 1, 2
• Do NOT use low-dose dopamine for renal protection (strong recommendation, Grade 1A) 1, 2
• Evidence clearly demonstrates dopamine's inferiority to norepinephrine in mortality outcomes 3

Phenylephrine (Salvage Only)

• NOT recommended except in three specific circumstances (Grade 1C) 1, 2:
  1. Norepinephrine causes serious arrhythmias
  2. Cardiac output is known to be high with persistently low blood pressure
  3. Salvage therapy when combined inotrope/vasopressor drugs and low-dose vasopressin have failed

Angiotensin II (Emerging Option)

• Reserved for catecholamine-refractory shock 6
• Post-hoc evidence suggests potential benefit in patients with acute kidney injury or elevated renin concentrations 6

Adjunctive Inotropic Support

Add dobutamine (up to 20 µg/kg/min) when evidence of persistent hypoperfusion exists despite adequate fluid loading and vasopressor use (weak recommendation, low quality evidence) 1. Titrate to perfusion endpoints and discontinue if worsening hypotension or arrhythmias develop 1.

Practical Implementation Algorithm

1. Start norepinephrine immediately after adequate fluid resuscitation (minimum 30 mL/kg crystalloids), targeting MAP 65 mmHg
2. If norepinephrine reaches 0.25-0.50 µg/kg/min without achieving target MAP:
   • Add vasopressin 0.03 units/minute (fixed dose), OR
   • Add epinephrine (titrate to effect)
3. If persistent hypoperfusion despite adequate MAP: Add dobutamine (up to 20 µg/kg/min)
4. Reserve dopamine only for bradycardic patients without arrhythmia risk
5. Reserve phenylephrine and angiotensin II for salvage situations only

Critical Monitoring

Place an arterial catheter as soon as practical in all patients requiring vasopressors (weak recommendation, very low quality evidence) 1.

Common Pitfalls to Avoid

• Never delay norepinephrine while pursuing aggressive fluid resuscitation—early vasopressor initiation (including via peripheral access) shortens hypotension duration and reduces fluid overload 7, 8
• Never use vasopressin as monotherapy for initial vasopressor support 1, 2
• Never escalate norepinephrine indefinitely—consider adding second-line agents when doses exceed 0.25-0.50 µg/kg/min rather than pushing to ≥1 µg/kg/min 4, 7
• Never use low-dose dopamine for renal protection—this practice is contraindicated by strong evidence 1, 2

Emerging Strategies

Recent evidence suggests potential benefits from early broad-spectrum vasopressor approaches and corticosteroid adjuncts (hydrocortisone 200 mg/day when hemodynamic stability cannot be achieved) 1, 9, 6. However, the core recommendation remains norepinephrine first-line with vasopressin or epinephrine as second-line agents based on the strongest guideline evidence 1, 2.